Traditional therapies with single-antigen or single-target approaches poorly address individual patient variation and have largely been unsuccessful. Because every cancer follows its own unique evolutionary path, a patient-specific, multi-antigen-target approach is critical to and the essence of the Imvax treatment.

The Imvax approach is “antigen-agnostic” and our proprietary methodology provides the immune system with the patient’s own unique multi-antigen tumor profile, telling the body where and what to fight. The resulting investigational therapy is designed to provide systemic, long-lasting immune response that specifically targets the tumor’s entire antigen profile, while simultaneously nullifying its immune-silencing ability.

Here’s how we do it: